Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors

Sep 23, 2026

Uploaded by Sarah

EGFR aberrant activation and overexpression drive many solid cancers and often lead to poor outcomes, while EGFR-targeted therapies show limited durability due to tumor heterogeneity and an immunosuppressive TME. To address this, the study develops Targeted Apoptotic Immune Modulators (TAIM), a nonviral nanoparticle platform delivering polyinosine:polycytosine (polyIC) to trigger tumor cell death and antitumor immunity. The first TAIM, TAR001, selectively engages EGFR-overexpressing cancers, activating pattern recognition, apoptosis, cytokine secretion, and immune recruitment, extending survival and inhibiting growth across multiple murine models. The approach targets cancers including metastatic head and neck, NSCLC, colorectal, renal, and triple-negative breast cancer.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages10

Reading Time25 min

AccessFree to download

Introduction

TAIM platform and TAR001 mechanism

Selectivity and immune activation

In vivo efficacy and therapeutic significance

RESEARCH ARTICLE APPLIED BIOLOGICAL SCIENCES Targeted apoptotic immune modulator for the treatment of metastatic EGFR-positive solid tumors Derrick Brokaa, Shoshana Kleinb, Alexei Shira, b, Babette Schadea, Meera Saxenaa, Athanasia Dasargyria, Anita Jarzebinskaa, Caroline De Feytera, Davor Bajica, David Colecchiaa, Lucia D'Amicoa, Eric Kitasa, Elad Hikric,d, Michal Jerzy Skowickie, Michal Jerzy Okoniewskif, Laura Baldinog, Besnik Qeriqih, Elisa de Stanchinah, Joerg Schreiberi,1, Melanie Buchij, Cornelia G. Palivane , Yaakov Benensoni, Alfred ZippeliusJ, Doriano Fabbroa, Maurizio Scaltritig, Aviram Mizrachic,d, Alexander Levitzkib,2, Esteban Pombo-Villara, and Maya Ziglera,2 Affiliations are included on p. 9. Contributed by Alexander Levitzki; received January 21, 2025; accepted April 16, 2025; reviewed by Moran Benhar, Pedro Romero, and Keri Schadler Aberrant activation and overexpression of the epidermal growth factor receptor (EGFR) occurs in various solid cancers and often correlates with poor outcome. The clinical benefit from EGFR-targeted therapies is usually short-lived, with resistance being driven by tumor heterogeneity and an immunosuppressive tumor microenvironment (TME). To address these limitations, we developed Targeted Apoptotic Immune Modulators (TAIM), a nonviral nanoparticle platform for the targeted delivery of polyinosine:polycytosine (polyIC), to simultaneously induce tumor cell death and activate antitumor immunity. The first TAIM compound, TAR001, was designed asa systemic treatment against metastatic EGFR-positive solid cancers. Here, we present TAR001’s multifaceted mode of action. We demonstrate that TAR001 is selective toward EGFR-overexpressing cancers, provoking a pattern recognition response, apoptosis, cytokine secretion, and antitumor immunity. TAR001 modulates the TME, recruiting and activating both innate and adaptive immune cells. Systemic delivery of TAR001 markedly extends survival and inhibits tumor growth in multiple murine tumor models. TAR001 represents an innovative, safe, multimodal treatment approach with the potential to benefit patients with metastatic head and neck, non–small cell lung cancer, colorectal, renal, and triple-negative breast cancers. This unique modality utilizes a broad range of mechanisms to overcome the tumor’s ability to escape apoptosis and immune cell activation. EGFR | targeted cancer therapy | immunotherapy | nanoparticle | polyIC In recent years, immune checkpoint inhibition (ICI) has taken the center stage in cancer therapeutics. While significant improvements in solid tumor treatment have been made with the development and utilization of ICI alone or in combination, these treatments offer limited benefit for most patients with metastatic disease (1, 2), including patients with Epidermal Growth Factor Receptor (EGFR, also known as HER1/ErbB-1)-driven tumors, which tend to have a cold, immunosuppressive tumor microenvironment (TME) (3–7) . EGFR activating mutations, gene amplification, and/or protein overexpression are linked to many human cancers, including those of the head and neck (HN), breast, brain, lung, and colon (8), and typically correlate with more aggressive disease (3, 9–11) . Recent advances in the treatment of EGFR-driven cancers include tyrosine kinase inhibitors (TKI), antibodies, antibody–drug conjugates (ADC), and bispecific antibodies, such asthe recently approved Amivantamab, which targets both EGFR and Mesenchymal Epithelial Transition (MET) (12, 13) . Nevertheless, there is an unmet need for novel therapies that can surmount both tumor heterogeneity and the suppressive TME (14) . To overcome these hurdles, we have developed a targeted nanoparticle platform, Targeted Apoptotic Immune Modulator (TAIM). Targeting, a critical aspect of nanoparticle drug delivery, enables selectivity and reduces nonspecific toxicity. TAIMs are designed to selectively kill cancer cells, while simultaneously activating both the innate and

FAQs

What evidence supports TAR001’s effectiveness?

Systemic delivery of TAR001 markedly extends survival and inhibits tumor growth in multiple murine tumor models, with activity against EGFR-overexpressing cancers.

Sep 23, 2026

Uploaded by Sarah